6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.

Amiloride / analogs & derivatives Diuretics / pharmacology Humans Neoplasm Metastasis / drug therapy Structure-Activity Relationship Urokinase-Type Plasminogen Activator / antagonists & inhibitors
Amiloride Anti-metastatic Cancer Metastasis Selective optimisation of side-activity Trypsin-like serine protease Urokinase plasminogen activator uPA

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 12 2019
Historique:
received: 30 08 2019
revised: 10 10 2019
accepted: 11 10 2019
pubmed: 5 11 2019
medline: 25 9 2020
entrez: 5 11 2019
Statut: ppublish

Résumé

The oral K+-sparing diuretic amiloride shows anti-cancer side-activities in multiple rodent models. These effects appear to arise, at least in part, through moderate inhibition of the urokinase-type plasminogen activator (uPA, K

Identifiants

DOI: 10.1016/j.bmcl.2019.126753 PMID: 31679971 PMC: PMC7362394
pubmed: 31679971
pii: S0960-894X(19)30716-4
doi: 10.1016/j.bmcl.2019.126753
pmc: PMC7362394
mid: NIHMS1606809
pii:
doi:

Substances chimiques

Diuretics 0
Amiloride 7DZO8EB0Z3
Urokinase-Type Plasminogen Activator EC 3.4.21.73

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126753

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM115327
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Membr Biol. 1988 Oct;105(1):1-21
pubmed: 2852254
J Med Chem. 1967 Jan;10(1):66-75
pubmed: 6031705
Org Biomol Chem. 2013 Jun 14;11(22):3583-602
pubmed: 23632914
J Med Chem. 2019 Feb 28;62(4):2172-2183
pubmed: 30707839
Oncotarget. 2017 Apr 4;8(14):23099-23109
pubmed: 28416743
Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
pubmed: 10949579
Nat Rev Cancer. 2006 Oct;6(10):764-75
pubmed: 16990854
J Med Chem. 2016 May 26;59(10):4769-77
pubmed: 27124340
Clin Pharmacol Ther. 1969 Jan-Feb;10(1):50-63
pubmed: 4884296
Int J Cancer. 2011 Nov 1;129(9):2051-61
pubmed: 21544803
Br J Cancer. 1994 Oct;70(4):617-24
pubmed: 7917906
Structure. 2000 May 15;8(5):553-63
pubmed: 10801494
Cancer Res. 2000 Feb 1;60(3):636-43
pubmed: 10676647
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1050-60
pubmed: 24721891
J Biol Chem. 2004 Aug 6;279(32):33613-22
pubmed: 15150279
Curr Cancer Drug Targets. 2009 Feb;9(1):32-71
pubmed: 19200050
Eur Biophys J. 2002 Mar;31(1):26-35
pubmed: 12046895
J Med Chem. 2004 Mar 11;47(6):1303-14
pubmed: 14998318
Biochemistry. 2001 Oct 9;40(40):12157-68
pubmed: 11580291
Semin Nephrol. 1988 Sep;8(3):242-8
pubmed: 2849182
Nat Chem Biol. 2014 Aug;10(8):656-63
pubmed: 24997602
Channels (Austin). 2016 Nov;10(6):498-506
pubmed: 27367557
Br J Pharmacol. 1978 May;63(1):139-49
pubmed: 647157
Bioorg Med Chem Lett. 2009 May 1;19(9):2514-8
pubmed: 19339181
Int J Cancer. 1997 Jul 3;72(1):1-22
pubmed: 9212216
J Med Chem. 2018 Sep 27;61(18):8299-8320
pubmed: 30130401
J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
pubmed: 11792750
FEBS Lett. 1987 Apr 6;214(1):187-91
pubmed: 3106085
Biochemistry. 2001 Aug 7;40(31):9125-31
pubmed: 11478879
J Mol Biol. 2000 Aug 11;301(2):465-75
pubmed: 10926521
Medchemcomm. 2017 May 1;8(5):1022-1036
pubmed: 28798862
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581

Auteurs

Benjamin J Buckley (BJ)

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia; Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia.

Hiwa Majed (H)

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia; Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia.

Ashraf Aboelela (A)

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia; Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia.

Elahe Minaei (E)

Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia.

Longguang Jiang (L)

National Joint Biomdical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fuzhou 350116, China.

Karen Fildes (K)

Illawarra Health and Medical Research Institute, NSW 2522, Australia; Graduate School of Medicine, University of Wollongong, NSW 2522, Australia.

Chen-Yi Cheung (CY)

Department of Microbiology and Immunology, University of Otago, Otago 9016, New Zealand.

Darren Johnson (D)

Tri-institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, NY 10065, USA.

Daniel Bachovchin (D)

Tri-institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, NY 10065, USA; Chemical Biology Program, Memorial Sloan Kettering Cancer Centre, NY 10065, USA.

Gregory M Cook (GM)

Department of Microbiology and Immunology, University of Otago, Otago 9016, New Zealand.

Mingdong Huang (M)

National Joint Biomdical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fuzhou 350116, China.

Marie Ranson (M)

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia; Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia. Electronic address: mranson@uow.edu.au.

Michael J Kelso (MJ)

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia; Illawarra Health and Medical Research Institute, NSW 2522, Australia; Molecular Horizons, University of Wollongong, NSW 2522, Australia. Electronic address: mkelso@uow.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrazines › Amiloride › 6-Substituted amiloride derivatives as...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Diurétiques › 6-Substituted amiloride derivatives as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › 6-Substituted amiloride derivatives as...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › 6-Substituted amiloride derivatives as...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › 6-Substituted amiloride derivatives as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du sang › Activateurs du plasminogène › Activateur du plasminogène de type urokinase › 6-Substituted amiloride derivatives as...